Advicenne - Asset Resilience Ratio

Latest as of June 2025: 7.65%

Advicenne (ALDVI) has an Asset Resilience Ratio of 7.65% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Advicenne (ALDVI) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€515.00K
≈ $602.09K USD Cash + Short-term Investments

Total Assets

€6.73 Million
≈ $7.87 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Advicenne's Asset Resilience Ratio has changed over time. See Advicenne shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Advicenne's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Advicenne market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €515.00K 7.65%
Short-term Investments €0.00 0%
Total Liquid Assets €515.00K 7.65%

Asset Resilience Insights

  • Limited Liquidity: Advicenne maintains only 7.65% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Advicenne Industry Peers by Asset Resilience Ratio

Compare Advicenne's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Ascendis Pharma AS
F:A71
Biotechnology 0.00%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 1.39%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shanghai Shen Lian Biomedical Corp
SHG:688098
Biotechnology 3.87%

Annual Asset Resilience Ratio for Advicenne (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Advicenne.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 34.17% €3.25 Million
≈ $3.80 Million
€9.51 Million
≈ $11.11 Million
-0.09pp
2023-12-31 34.26% €4.25 Million
≈ $4.97 Million
€12.41 Million
≈ $14.51 Million
-24.12pp
2022-12-31 58.38% €8.32 Million
≈ $9.73 Million
€14.26 Million
≈ $16.67 Million
-8.81pp
2021-12-31 67.18% €12.69 Million
≈ $14.83 Million
€18.88 Million
≈ $22.07 Million
-2.68pp
2020-12-31 69.87% €16.77 Million
≈ $19.61 Million
€24.00 Million
≈ $28.06 Million
-12.39pp
2019-12-31 82.26% €18.85 Million
≈ $22.04 Million
€22.92 Million
≈ $26.80 Million
+1.96pp
2018-12-31 80.30% €26.64 Million
≈ $31.14 Million
€33.17 Million
≈ $38.78 Million
-14.18pp
2017-12-31 94.47% €36.48 Million
≈ $42.65 Million
€38.62 Million
≈ $45.15 Million
+45.86pp
2016-12-31 48.62% €1.58 Million
≈ $1.85 Million
€3.26 Million
≈ $3.81 Million
-3.13pp
2015-12-31 51.75% €1.54 Million
≈ $1.80 Million
€2.98 Million
≈ $3.48 Million
+7.10pp
2014-12-31 44.65% €1.44 Million
≈ $1.68 Million
€3.22 Million
≈ $3.77 Million
--
pp = percentage points

About Advicenne

PA:ALDVI France Biotechnology
Market Cap
$20.79 Million
€17.78 Million EUR
Market Cap Rank
#24874 Global
#406 in France
Share Price
€1.22
Change (1 day)
-0.65%
52-Week Range
€1.13 - €2.19
All Time High
€15.27
About

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or co… Read more